Fluconazole
4.1 Therapeutic indications
Adults
Treatment of mycoses caused by Candida, Cryptococci and other susceptible yeasts, in particular:
• Systemic candidiasis (including disseminated deep infections and peritonitis)
• Severe mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis and non-invasive bronchopulmonary candidiasis), where oral treatment is not possible.
• Cryptococcal meningitis in adults
• Prophylaxis against deep Candida infections (especially Candida albicans) in patients with neutropenia due to bone marrow transplantation.
Consideration should be given to official guidance on the appropriate use of antifungal agents. Before initiating treatment samples should be taken for microbiological analysis and the suitability of the therapy should subsequently be confirmed (see sections 4.2 and 5.1).
In some patients with severe cryptococcal meningitis the mycological response during fluconazole treatment may be slower compared to other treatments (see section 4.4).
Children and adolescents
Treatment of mycoses caused by Candida and other susceptible yeasts, in particular:
• Systemic candidiasis (including disseminated deep infections and peritonitis)
• Severe mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis and non-invasive bronchopulmonary candidiasis), where oral treatment is not possible.
Consideration should be given to official guidance on the appropriate use of antifungal agents. Before initiating treatment samples should be taken for microbiological analysis and the suitability of the therapy should subsequently be confirmed (see sections 4.2 and 5.1).
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Disclaimer
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drug Licencing
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).